Effectiveness and safety of long-term therapy with alirocumab in acute coronary syndrome patients: A single-centre retrospective real-world study.

Abstract

Aims: Although guidelines recommend in-hospital initiation of high-intensity statin therapy in patients with acute coronary syndromes (ACS), low-density lipoprotein cholesterol (LDL-C) target levels are frequently not attained. Alirocumab has been demonstrated to be a fast-acting and efficacious agent for lowering LDL-C in controlled trials. However, there is a paucity of real-world evidence concerning its use in patients of Chinese ethnicity with ACS. This real-world observational study aimed to assess the efficacy and safety of alirocumab in Chinese ACS patients.

Methods: This study is a single-centre, retrospective study involving 73 patients with ACS treated with alirocumab over 6 months, followed up at 1, 3, 6 and 12 months, the main observation measure is the achieved rate of LDL-C levels after treatment with alirocumab at 6 months.

Results: In comparison with baseline, alirocumab therapy for 6 months was associated with a significant increase in percentage of patients who attained the control goal of LDL-C <1.0 mmol/L (51.3 vs. 1.4%, P < .0001) and <1.4 mmol/L (61.5 vs. 5.5%, P < .0001), respectively.

Conclusion: There was a significant reduction in LDL-C levels with alirocumab with or without lipid-lowering therapy treatment in ACS patients in this real-world evidence study. The percentage of patients achieving LDL-C goals of <1.00 and <1.40 mmol/L were significantly higher than baseline 6 months after the adding alirocumab.